InvestSMART

Medical Developments International Limited (ASX:MVP)

ALERT: Price-sensitive ASX Announcement for MVP
Current share price for MVP : $0.400 0.015 (3.90%)+
Announcement
Release
24 Apr 2026 8:58AM
Price at Release
$0.385
Full Release
download
Summary
Medical Developments International (MVP) released its Appendix 4C and Quarterly Activity Report for Q3 FY26, highlighting positive free cashflow and significant growth in their Pain Management segment, primarily driven by Penthrox. The company reported a cash balance of $18.7 million at the end of March 2026. Group revenue increased to $10.5 million due to a 26% rise in Penthrox volumes in Australian hospitals and a 19% increase in European markets. However, respiratory revenue saw a decline. MVP's outlook for FY26 includes advancing paediatric approvals in Europe, alongside strategic initiatives aimed at expanding market access and enhancing clinical engagement. Despite potential supply chain disruptions, impacts are expected to be minimal for FY26.
Key Points
  • Positive free cashflow for Q3 and YTD.
  • Penthrox revenue up $4.9 million.
  • Penthrox volume growth of 26% in the Australian hospital segment.
  • European in-market Penthrox volume growth of 19%.
  • Penthrox paediatric label approvals in Europe close to completion.
  • Cash balance at 31 March 2026 of $18.7 million.
  • Group revenue for Q3 FY26 was $10.5 million, $1.6 million higher than the prior corresponding period.
  • Pain Management revenue was $8.4 million for the quarter, $2.7 million higher than the prior corresponding period.
  • Respiratory revenue was $2.2 million for the quarter, down $1.0 million on the prior corresponding period.
  • The Group generated $2.5 million cash from operating activities during Q3 FY26.
  • Cash used in investing activities during the quarter was $0.2 million, and cash used in financing activities was $0.1 million.
  • FY26 Outlook included finalising approvals for the paediatric indication in Europe and executing targeted medical and commercial initiatives.
  • Expect earnings in the Respiratory segment to be lower in the second half of FY26 compared to the first half.
IMPORTANT NOTE: This information is autogenerated and has not been reviewed for accuracy or completeness. You should refer to the full announcement here for further information.